IndustryCompany release

Vericel lifts 2026 guidance after Q3 revenue rises 26% to $85.4m

🇺🇸 Vericel Corp (VCEL) · Thu 05 Nov 2026

The cell therapy maker reported third-quarter net income of $14.2m, raised full-year revenue and adjusted EBITDA margin guidance, and said a possible 2027 UK launch of MACI remains on track.

Vericel Corp reported results for the quarter ended 30 September 2026 on 5 November, posting net revenue of $85.4m, a 26% increase. Net income for the quarter was $14.2m.

MACI, the company's knee cartilage repair product, generated $67.4m of the total. The Burn Care franchise, which comprises Epicel and NexoBrid, contributed $18.0m.

On the back of the quarter, Vericel raised its 2026 revenue guidance to a range of $344m to $346m. It also lifted its adjusted EBITDA margin guidance to 28%.

The company said a potential UK launch of MACI in 2027 remains on track. The information available does not detail the regulatory pathway or timing milestones for that launch, so the status of any UK approval steps cannot be confirmed from the material on file.

What it means for your team

  • Market-access teams in the UK should note that Vericel still points to a possible 2027 MACI launch, which could bring a new cartilage repair option into reimbursement and commissioning discussions.
  • Regulatory teams tracking advanced therapies should watch for further detail from Vericel on the UK submission and approval timeline, which is not specified in the current information.
  • MACI accounts for the large majority of quarterly revenue, so any supply, quality or regulatory development affecting the product would carry weight for the company's overall performance.

Company's press release (SEC filing): Vericel Corp ↗

Article written by VigiEye from the official source (Vericel Corp). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →